Physician profile
James B Blankenship
NPI 1245202274
$217,385.11
in general payments reported to CMS, 2019-2025
7 companies · $40K in 2025
The $40K reported for 2025 was more than what 94% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $37K · 2021: $31K · 2022: $42K · 2023: $34K · 2024: $31.87 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $68K · Consulting Fee: $3,450 · Travel and Lodging: $2,777 · Food and Beverage: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $67,955.17 |
| Consulting Fee | $3,450.00 |
| Travel and Lodging | $2,777.38 |
| Food and Beverage | $268.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| The Institute of Musculoskeletal Science and Education | $197,818.63 | 2019-2025 | Enza, Spira |
| Camber Spine Technologies LLC | $19,059.88 | 2019-2023 | |
| Philadelphia Medical Management Company LLC | $321.08 | 2020-2021 | |
| Shockwave Medical, INC | $79.63 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Midsouth Orthopedics INC. | $54.47 | 2021 | |
| Abbott Laboratories | $40.14 | 2024-2025 | Proclaim |
| Novo Nordisk INC | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$700,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Blankenship listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.